High doses of DNR (2 μM) enabled the switch of LC3-I into LC3-II and were accompanied with a significant increased expression level of LC3 in DNR-treated myeloid leukemia cell lines K562 and KG1a (Figure 1B and Figure S1A). This evidence concerns the gene MAP1LC3A and myeloid leukemia.